| - |
Aspirin 81mg/Esomeprazole 20mg |
Axanum® |
Prevention of thrombotic cardiovascular and cerebrovascular events in patients requiring continuous low-dose acetylsalicylic acid treatment, and who are in need of prophylaxis against acetylsalicylic acid associated gastric and /or duodenal ulcers. |
Rapid Review Complete |
16th May 2012 |
 |
| - |
Ataluren |
Translarna® |
For the treatment of DMD resulting from a nonsense mutation in the dystrophin gene, in ambulatory patients aged 5 years and older. The presence of a nonsense mutation in the dystrophin gene should be determined by genetic testing. |
NCPE Assessment Process Complete |
29th April 2016 |
|
| - |
Atezolizumab |
Tecentriq® |
For the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC) after prior platinum-containing chemotherapy. |
Rapid Review Complete |
7th June 2019 |
|
| - |
Atezolizumab |
Tecentriq® |
As monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic NSCLC after prior chemotherapy. Patients with EGFR activating mutations or ALK‑positive tumour mutations should also have received targeted therapy before receiving atezolizumab. |
NCPE Assessment Process Complete |
25th September 2018 |
|
| 21012 |
Atezolizumab |
Tecentriq® |
As monotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have a PD-L1 expression ≥50% tumour cells (TC) or ≥10% tumour-infiltrating immune cells (IC) and who do not have EGFR mutant or ALK-positive NSCLC. |
Rapid Review Complete |
21st April 2021 |
|
| 22036 |
Atezolizumab |
Tecentriq® |
As an adjuvant treatment following complete resection and platinum-based chemotherapy for adult patients with NSCLC with a high risk of recurrence whose tumours have PD-L1 expression on ≥ 50% of tumour cells and who do not have EGFR mutant or ALK-positive NSCLC. |
NCPE Assessment Process Complete |
15th May 2024 |
|
| - |
Atezolizumab |
Tecentriq® |
In combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer whose tumours have PD-L1 expression ≥ 1% and who have not received prior chemotherapy for metastatic disease. |
NCPE Assessment Process Complete |
1st September 2020 |
|
| 19030 |
Atezolizumab |
Tecentriq® |
In combination with carboplatin and etoposide is indicated for first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC). |
NCPE Assessment Process Complete |
24th September 2020 |
|
| 20060 |
Atezolizumab in combination with bevacizumab |
Tecentriq® |
For the treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have not received prior systemic therapy. |
NCPE Assessment Process Complete |
5th June 2024 |
|
| 20039 |
Atezolizumab |
Tecentriq® |
Atezolizumab monotherapy is indicated as treatment of locally advanced or metastatic urothelial carcinoma (LaMUC) in adult patients who are considered cisplatin-ineligible and whose tumours have PD-L1 expression ≥5%. |
Rapid Review Complete |
23rd September 2020 |
|
| 21009 |
Atidarsagene autotemcel |
Libmeldy® |
For the treatment of metachromatic leukodystrophy characterized by biallelic mutations in the ARSA gene leading to a reduction of the ARSA enzymatic activity, in children with late infantile or early juvenile forms without clinical manifestations of the disease, and in children with the early juvenile form, with early clinical manifestations of the disease, who still have the ability to walk independently and before the onset of cognitive decline. |
NCPE Assessment Process Complete |
24th January 2024 |
|
| 23059 |
Atogepant |
Aquipta® |
Atogepant is indicated for the prophylaxis of migraine in adults who have at least four migraine days per month. |
Rapid Review Complete |
11th March 2025 |
|
| 23039 |
Atogepant |
Aquipta® |
Prophylaxis of migraine in adults who have at least 4 migraine days per month |
Rapid Review Complete |
11th March 2025 |
|
| 21005 |
Autologous anti-CD19-transduced CD3+ cells |
Tecartus® |
For the treatment of adult patients with relapsed or refractory mantle cell lymphoma after two or more lines of systemic therapy including a Bruton’s tyrosine kinase inhibitor. |
Rapid Review Complete |
17th July 2023 |
|
| 22009 |
Avacopan |
Tavneos® |
In combination with a rituximab or cyclophosphamide regimen, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis or microscopic polyangiitis. |
NCPE Assessment Process Complete |
5th June 2024 |
|
| - |
Avanafil |
Spedra® |
For the treatment of erectile dysfunction in adult men. |
Rapid Review Complete |
2nd May 2014 |
|
| 25026 |
Avapritinib |
Ayvakyt® |
Avapritinib is indicated for the treatment of adult patients with indolent systemic mastocytosis (ISM) with moderate to severe symptoms inadequately controlled on symptomatic treatment. |
Rapid Review Complete |
17th April 2025 |
|
| 25031 |
Avapritinib |
Ayvakyt® |
Avapritinib (Ayvakyt®) is indicated as monotherapy for the treatment of adult patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated haematological neoplasm (SM-AHN) or mast cell leukaemia (MCL), after at least one systemic therapy. |
Rapid Review Complete |
15th May 2025 |
|
| 20006 |
Avatrombopag |
Doptelet® |
For the treatment of severe thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo an invasive procedure. |
Rapid Review Complete |
2nd April 2020 |
|
| 20058 |
Avatrombopag |
Doptelet® |
For the treatment of primary chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments (e.g. corticosteroids, immunoglobulins). |
Rapid Review Complete |
15th February 2021 |
|
| - |
Avelumab |
Bavencio® |
For the treatment of adults with metastatic Merkel Cell Carcinoma. |
NCPE Assessment Process Complete |
9th October 2018 |
|
| 19046 |
Avelumab |
Bavencio® |
Avelumab in combination with axitinib is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma. |
NCPE Assessment Process Complete |
23rd June 2021 |
|
| 21001 |
Avelumab |
Bavencio® |
As monotherapy for the first-line maintenance treatment of adult patients with locally advanced or metastatic urothelial carcinoma whose disease has not progressed with first line platinum-based induction chemotherapy. |
NCPE Assessment Process Complete |
22nd December 2021 |
|
| - |
Axicabtagene Ciloleucel |
Yescarta® |
For the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL), after two or more lines of systemic therapy. |
NCPE Assessment Process Complete |
25th February 2020 |
|
| 22066 |
Axicabtagene ciloleucel |
Yescarta® |
For the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. |
NCPE Assessment Process complete |
16th October 2024 |
|
| - |
Axitinib |
Inlyta® |
For the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of prior treatment with sunitinib or a cytokine |
Rapid Review Complete |
20th November 2012 |
|
| - |
Azelastine hydrochloride and fluticasone propionate (nasal spray) |
Dymista® |
For symptomatic treatment of moderate-to-severe allergic rhinitis, in patients aged 12 years and older for whom monotherapy with either intranasal antihistamine or glucocorticoid is not considered sufficient. |
Rapid Review Complete |
28th February 2013 |
|
| - |
Azilsartan |
Edarbi® |
For the treatment of essential hypertension in adults. |
Rapid Review Complete |
11th January 2012 |
|
| 24037 |
Aztreonam-avibactam |
Emblaveo® |
For the treatment of the following infections in adult patients: • Complicated intra-abdominal infection (cIAI) • Hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP) • Complicated urinary tract infection (cUTI), including pyelonephritis. Aztreonam-avibactam is also indicated for the treatment of infections due to aerobic Gram-negative organisms in adult patients with limited treatment options. |
Rapid Review complete |
25th October 2024 |
|
| 21050 |
Baricitinib |
Olumiant® |
Treatment of moderate to severe atopic dermatitis in adult patients who are candidates for systemic therapy. |
Rapid Review complete |
16th December 2021 |
|
| - |
Baricitinib |
Olumiant® |
Treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs. Baricitinib may be used as monotherapy or in combination with methotrexate. |
Rapid Review complete |
13th July 2017 |
|
| 20056 |
Baricitinib |
Olumiant® |
Treatment of moderate to severe atopic dermatitis in adult patients who are candidates for systemic therapy. |
Rapid Review complete |
28th January 2021 |
|
| - |
Bazedoxifene |
Conbriza® |
Treatment of postmenopausal osteoporosis in women at increased risk of fracture. A significant reduction in the incidence of verterbral fractures has been demonstrated; efficacy on hip fractures has not been established. |
Rapid Review complete |
2nd January 2011 |
|
| 23037 |
Beclometasone /formoterol |
Fostair® |
Beclometasone / formoterol (Fostair®) for COPD. HTA ID 23037 Symptomatic treatment of patients with severe chronic obstructive pulmonary disease [COPD] (forced expiratory volume [FEV1] <50% predicted normal) and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators. |
Rapid Review Complete |
20th July 2023 |
|
| 23033 |
Beclometasone dipropionate anhydrous + formoterol fumarate dihydrate + glycopyrronium bromide |
Trimbow® |
Beclometasone dipropionate anhydrous + formoterol fumarate dihydrate + glycopyrronium bromide (Trimbow®) is indicated for maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disorder (COPD) who are not adequately treated by a combination of an inhaled corticosteroid (ICS) and a long-acting beta2-agonist (LABA) or a combination of a long-acting beta2-agonist (LABA) and a long-acting muscarinic antagonist (LAMA). |
Rapid Review Complete |
19th July 2023 |
|
| 23034 |
Beclometasone dipropionate anhydrous + formoterol fumarate dihydrate + glycopyrronium bromide |
Trimbow® |
Beclometasone dipropionate anhydrous + formoterol fumarate dihydrate + glycopyrronium bromide (Trimbow®) for the maintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and a medium or high dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year |
Rapid Review Complete |
19th July 2023 |
|
| 23038 |
Beclometasone/formoterol |
Fostair® |
Beclometasone/formoterol (Fostair®) is indicated for the regular treatment of asthma where use of a combination product (inhaled corticosteroid [ICS] and long-acting beta2-agonist [LABA]) is appropriate: -in patients not adequately controlled with ICS and 'as needed' inhaled rapid-acting beta2-agonist; or -in patients already adequately controlled on both ICS and LABA. |
Rapid Review Complete |
20th July 2023 |
|
| - |
Bedaquiline |
Sirturo® |
For use as part of an appropriate combination regimen for pulmonary MDR‑TB in adult patients when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability. Consideration should be given to official guidance on the appropriate use of antibacterial agents. |
Rapid Review complete |
20th February 2015 |
|
| - |
Belatacept |
Nulojix® |
In combination with corticosteroids and a mycophenolic acid (MPA), for prophylaxis of graft rejection in adults receiving a renal transplant. It is recommended to add an interleukin (IL)-2 receptor antagonist for induction therapy to this belatacept-based regimen. |
Rapid Review complete |
23rd January 2012 |
|
| - |
Belimumab |
Benlysta® |
As add-on therapy in adult patients with active, autoantibody-positive systemic lupus erythematosus (SLE) with a high degree of disease activity (e.g., positive anti-dsDNA and low complement) despite standard therapy. |
Rapid Review complete |
31st August 2011 |
|
| 23021 |
Belimumab |
Benlysta® |
Belimumab is indicated in combination with background immunosuppressive therapies for the treatment of adult patients with active lupus nephritis. |
Rapid Review Complete |
16th May 2023 |
|
| 23022 |
Belimumab |
Benlysta® |
Belimumab is indicated as add-on therapy in patients aged five years and older with active, autoantibody-positive systemic lupus erythematosus with a high degree of disease activity (e.g., positive anti-dsDNA and low complement) despite standard therapy. |
Rapid Review Complete |
29th May 2023 |
|
| 25020 |
Belzutifan |
Welireg® |
Belzutifan is indicated for the treatment of adult patients with von Hippel-Lindau disease who require therapy for associated, localised renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumours (pNET), and for whom localised procedures are unsuitable. |
Awaiting full HTA submission from Applicant |
28th March 2025 |
|
| 20026a |
Bempedoic acid |
Nilemdo® |
In adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidemia, as an adjunct to diet: In combination with a statin or statin with other lipid-lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin, OR Alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated |
NCPE Assessment process complete |
16th November 2021 |
|
| 20026b |
Bempedoic acid/Ezetimibe |
Nustendi® |
In adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet (a) in combination with a statin in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin in addition to ezetimibe (b) alone in patients who are either statin – intolerant or for whom a statin is contraindicated and are unable to reach LDL-C goals with ezetimibe alone and (c) in patients already being treated with the combination of bempedoic acid and ezetimibe as separate tablets with or without a statin. |
NCPE Assessment Process Complete |
16th November 2021 |
|
| - |
Bendamustine |
Levact® |
Treatment of Chronic Lymphocytic Leukaemia (CLL) |
NCPE Assessment Process Complete |
20th November 2012 |
|
| - |
Benralizumab |
Fasenra® |
As add-on maintenance treatment in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus long-acting β-agonists. |
Rapid Review complete |
14th February 2018 |
|
| 20018 |
Benralizumab |
Fasenra® |
As an add-on maintenance treatment in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus long-acting β-agonists. |
Rapid Review complete |
28th April 2020 |
|
| 22031 |
Berotralstat |
Orladeyo® |
Routine prevention of recurrent attacks of hereditary angioedema in adult and adolescent patients aged 12 years and older |
Rapid Review Complete |
28th March 2023 |
|
| - |
Bezlotoxumab |
Zinplava® |
Prevention of recurrence of Clostridium difficile infection (CDI) in adults at high risk for recurrence of CDI. |
Rapid Review complete |
14th June 2017 |
|
